Pular para o conteúdo principal
Ranking Invest

ZVRA - Zevra Therapeutics, Inc.

Segmento: HealthcareZevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Análise Ranking Invest

Valuation estimado
$ 206.81 Mi
Valor de Mercado
$ 713.20 Mi
Sobrepreço (AV)+244.9%
IVR
0.29A companhia vale 0,29 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.04O valuation alternativo equivale a -4% do valor de mercado da companhia.
MLL
-0.04O lucro líquido dos controladores em 16 trimestres equivale a -4% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 217.65 Mi

Dívida Líquida

-$ 145.32 Mi

L4T

$ 58.26 Mi

MM4T

40.06%

Indicadores Básicos

ROE

26.77%

Índices de Previsibilidade

Receita Líquida

G0.73

Lucro

F4.97

Margem

F2.53

Índices de Tendência

Receita Líquida

A10.61

Lucro

B5.46

Margem

B6.08

Índices de Endividamento

DIV/PAT

-0.67

DIV/L4T

-2.49

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.